Myasthenia Gravis News - LARVOL Sigma

Myasthenia Gravis	Welcome, Profile Billing Logout

«1 2...56 57 58 59 606162 63 64 65 66...136 137 »

|||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Rituximab for the treatment of late-onset generalized and refractory myasthenia gravis (B3) - Jul 18, 2022 - Abstract #EAN2022EAN_1291;
However, potential side effects related to chronic immunosuppression should be considered, particularly in older ones. Further studies are needed to assess the efficacy and safety of rituximab in this age group.

|||||||||| DOK7-associated congenital myasthenic syndrome: a differential diagnosis of core myopathies? (B3) - Jul 18, 2022 - Abstract #EAN2022EAN_1289;
Biopsy results may be misleading in cases like the one we present. There are scarce reports of core-like areas in muscle biopsy of patients with DOK7 mutations and their pathogenesis in CMS is unknown.

|||||||||| Myasthenia gravis treated in the neurology intensive care unit: a 14-year single centre experience (B3) - Jul 18, 2022 - Abstract #EAN2022EAN_1288;
Elder age is an independent predictor of lethal outcome in patients with severe MG exacerbation. Mechanical ventilation and a higher number of comorbidities lead to more frequent complications.

|||||||||| Tecentriq (atezolizumab) / Roche
Management of Lambert-Eaton Myasthenic Syndrome in the context of immunecheckpoint-inhibitor treatment - A Case Report (B3) - Jul 18, 2022 - Abstract #EAN2022EAN_1287;
Downside of treatment is a high rate of severe autoimmune phenomena. In our case, even a single course of Atezolizumab lead to clinical relevant exacerbation.

|||||||||| carbamazepine / Generic mfg.
Eyelid neuromyotonia in a patient with Myasthenia Gravis (B3) - Jul 18, 2022 - Abstract #EAN2022EAN_1286;
The coexistence of this syndrome with Myasthenia Gravis can represent a diagnostic challenge, mainly due to the need to distinguish eyelid neuromyotonia from myasthenic eyelid ptosis. We intend to highlight the importance of recognizing these subtle symptoms, as they require specific pharmacological treatment.

|||||||||| Journal: Peak expiratory flow and the single-breath counting test as markers of respiratory function in patients with myasthenia gravis. (Pubmed Central) - Jul 17, 2022
We intend to highlight the importance of recognizing these subtle symptoms, as they require specific pharmacological treatment. PEF, the single-breath counting test, and the mMRC scale are useful measures for evaluating respiratory function in patients with MG.

|||||||||| Journal: Clinicopathological-genetic features of congenital myasthenic syndrome from a Chinese neuromuscular centre. (Pubmed Central) - Jul 17, 2022
Prompt utilization of genetic testing will identify novel variants and expand our understanding of the phenotype of this rare syndrome. Our findings contribute to the clinical, pathohistological and genetic spectrum of congenital myasthenic syndrome in China.

|||||||||| Chirocaine (levobupivacaine) / Purdue, AbbVie
Journal: Anesthetic management of a patient with subclinical myasthenia gravis who underwent a thymectomy: a case report. (Pubmed Central) - Jul 17, 2022
We reported the anesthetic management of a patient with subclinical MG who underwent a thymectomy. Further research is necessary to clarify subclinical MG patients' sensitivity to rocuronium.

|||||||||| Journal: Safety and feasibility of a modularized procedure for trans-subxiphoid robotic extended thymectomy. (Pubmed Central) - Jul 17, 2022
Further research is necessary to clarify subclinical MG patients' sensitivity to rocuronium. The eight-step modularized technique of trans-subxiphoid robotic extended thymectomy was verified to be a safe, effective, radical procedure, which offers unique superiority over ectopic thymic tissue resection.

|||||||||| Clinical Differences Between Ocular and Generalized Myasthenia Gravis () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_597;

|||||||||| Serological Diagnostics of MuSK Myasthenia Gravis in South Korea: Comparison of ELISA, RIPA and CBA () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_596;

|||||||||| tolebrutinib (SAR442168) / Sanofi
Efficacy and Safety of Tolebrutinib in Adults with Generalized Myasthenia Gravis: Phase 3 Study Design () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_595;

|||||||||| Productivity Losses for Generalized Myasthenia Gravis Patients and their Caregivers: Association with Disease Severity () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_594;

|||||||||| Oral Tobacco, but Not Smoking, Is Associated With an Increased Risk of Myasthenia Gravis () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_593;

|||||||||| The Association Between QMG Scores and Health-related Quality of Life in Myasthenia Gravis Patients () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_592;

|||||||||| Promise-MG: Results of a Multicenter Comparative Effectiveness Study of Myasthenia Gravis Treatments () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_591;

|||||||||| Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Baseline Characteristics of Patients with Myasthenia Gravis Enrolled in an Expanded Access Programme for Efgartigimod () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_590;

|||||||||| zilucoplan (RA101495) / UCB
Zilucoplan in Myasthenia Gravis: Safety and Tolerability Results From the Phase 3 Randomised RAISE Study () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_589;

|||||||||| nipocalimab (M281) / J&J
Pharmacokinetics and Pharmacodynamics of Nipocalimab in Healthy Participants and Patients with Generalized Myasthenia Gravis () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_588;

|||||||||| Soliris (eculizumab) / AstraZeneca
Effectiveness of Eculizumab Treatment for Generalized Myasthenia Gravis in Us Clinical Practice: gMG Registry Data () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_587;

|||||||||| Clinical Characteristics of Patients With Seronegative Myasthenia Gravis () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_527;

|||||||||| Barriers and Facilitators to Exercise in Auto-Immune Myasthenia Gravis () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_526;

|||||||||| Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15 With Other Functional Scales () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_525;

|||||||||| azathioprine / Generic mfg.
Incidence of Skin Changes in Patients with Myasthenia Gravis Prescribed Mycophenolate or Azathioprine () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_524;

|||||||||| Myasthenia Gravis Demographics Re-Visited () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_523;

|||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Tocilizumab in Therapy Myasthenia Gravis Patients With COVID-19 () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_522;

|||||||||| COVID-19 and Vaccination Against SarsCoV-2 in Patients With Myasthenia Gravis From Belgrade, Serbia () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_483;

|||||||||| Quality of Life of Myasthenia Gravis Patients During COVID-19 Pandemic – One Year Follow Up () - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_469;

|||||||||| ISS12 Targeting complement to fight chronic burden in gMG (Silver Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_397;
The chronic and fluctuating nature of generalized myasthenia gravis (gMG) has a substantial impact on a patient’s daily life, including their physical, emotional, social, and economic wellbeing. This symposium will provide the opportunity to engage in discussion with our expert faculty, who will be considering the burden of this chronic disease and illustrating how terminal complement inhibition, which targets a primary driver of AChR Ab+ gMG, can improve patient outcomes.

|||||||||| ISS07 Managing Generalised Myasthenia Gravis: A Tale of Two Targets (Copper Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_373;
Pushpa Narayanaswami, James F. Howard, and Heinz Wiendl discuss the need for different targeted therapies in patients with generalised Myasthenia Gravis (gMG), and how these therapies could impact future therapeutic management. The symposium will focus on improving clinicians’: • Knowledge of the factors that contribute to disease progression in gMG • Ability to interpret emerging data for emerging therapies in the management of uncontrolled gMG and potential impact on practice • Ability to individualise care of patients with gMG

|||||||||| The 2020 Update of the International Consensus-based Treatment Recommendations for Myasthenia Gravis (Copper Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_329;

|||||||||| WS11: Evolving Autoantibody and Treatment Landscape in Myasthenia Gravis (Copper Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_326;
The symposium will focus on improving clinicians’: • Knowledge of the factors that contribute to disease progression in gMG • Ability to interpret emerging data for emerging therapies in the management of uncontrolled gMG and potential impact on practice • Ability to individualise care of patients with gMG Identify antibodies supportive of the diagnosis of autoimmune MG; Describe the clinical presentation of MG based on antibody status; Discuss the utility of newer serologic tests in diagnosing MG; Discuss promising therapies under development for autoimmune MG; Review cautionary medications that can compromise clinical status in MG; Review the 2020 updates international consensus recommendations for the treatment of MG; Discuss the implications of checkpoint inhibitor use in relation to MG;

|||||||||| Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Efficacy of Efgartigimod in Generalized Myasthenia Gravis: Myasthenia Gravis Composite Score Analysis From ADAPT (Meeting Studio 211 + 212) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_315;

|||||||||| Correlation Between Muscle MRI and Genotype in Myasthenic Syndromes (Meeting Studio 211 + 212) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_314;

|||||||||| Epidemiology of Myasthenia Gravis (Meeting Studio 211 + 212) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_313;

|||||||||| SBT-20 / Stealth BioTherapeutics
SS20: Clinical Research Update - Neuromuscular Transmission Disorders (Meeting Studio 211 + 212) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_312;
Identify antibodies supportive of the diagnosis of autoimmune MG; Describe the clinical presentation of MG based on antibody status; Discuss the utility of newer serologic tests in diagnosing MG; Discuss promising therapies under development for autoimmune MG; Review cautionary medications that can compromise clinical status in MG; Review the 2020 updates international consensus recommendations for the treatment of MG; Discuss the implications of checkpoint inhibitor use in relation to MG; This session will entertain the latest clinical and scientific developments in autoimmune mediated myasthenia gravis and congenital myasthenia related to epidemiology, pathophysiology and imaging.

|||||||||| Genetic Epidemiology of Congenital Myasthenic Syndromes (Meeting Studio 214 + 216) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_311;

|||||||||| SS21: Inherited Disorders of Neuromuscular Transmission (Meeting Studio 214 + 216) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_308;
This session will entertain the latest clinical and scientific developments in autoimmune mediated myasthenia gravis and congenital myasthenia related to epidemiology, pathophysiology and imaging. This session will cover the latest genetic and clinical discoveries for congenital myasthenic syndromes.

|||||||||| Role of Autoantibodies in Diagnosis, Treatment Choice and Monitoring of Myasthenia Gravis (Gold Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_303;

|||||||||| Pregnancy and Treatment Considerations in Myasthenia Gravis and Congenital Myasthenic Syndrome (Gold Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_302;

|||||||||| Clinical Trial Update for Myasthenia Gravis (Gold Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_301;

|||||||||| SS22 : Myasthenia Gravis Therapies (Gold Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_300;
This session will cover the latest genetic and clinical discoveries for congenital myasthenic syndromes. This session will entertain the latest clinical and scientific developments in autoimmune mediated myasthenia gravis.

|||||||||| Myasthenic Crisis (Copper Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_298;

|||||||||| The Emerging Treatment Landscape for Myasthenia Gravis (Gold Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_294;

|||||||||| Genetic Causes of Congenital Myasthenic Syndromes (Gold Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_293;

|||||||||| Mechanism of Disease and Therapeutic Rescue of DOK7 Congenital Myasthenia and MuSK-Myasthenia Gravis (Gold Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_292;

|||||||||| Plenary 4: New Developments in Diagnosis and Treatment of Myasthenia Gravis and Congenital Myasthenic Syndrome (Gold Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_291;
This session will entertain the latest clinical and scientific developments in autoimmune mediated myasthenia gravis. This session will highlight new developments in diagnosis and treatment of autoimmune and genetic neuromuscular transmission disorders.

|||||||||| Immunosuppressive Therapy as Risk Factor for Severe SARS-CoV-2 Infection in Myasthenia Gravis (Meeting Studio 214 + 216) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_138;

|||||||||| rozanolixizumab (UCB7665) / UCB
Rozanolixizumab in Generalized Myasthenia Gravis: Responder Analyses From the Phase 3 MycarinG Study (Meeting Studio 214 + 216) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_134;

|||||||||| Myasthenic Syndromes (Gold Hall) - Jul 17, 2022 - Abstract #ICNMD2022ICNMD_116;



	Diseases Companies Products Productz Mechanisms of Action Sites